Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449392 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Migraine is a cyclic condition with attacks consisting mainly of intense headaches, sensory intolerance, and nausea or vomiting. Loss of consciousness during attacks is often attributed exclusively to a neurally mediated reflex to pain, although it may also be due to migraine's autonomic impairment, with cardiac conduction abnormalities, probably in relation to a degree of reduced sympathetic function. We report the case of a 51-year-old woman presenting episodes of syncope exclusively after vomiting during migraine attacks.
View Article and Find Full Text PDFCycling sensitivity across migraine phases: A longitudinal case-control study.
Eur J Pain
January 2025
Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Functional neuroimaging studies indicate that central transmission of trigeminal pain may commence up to 48 h prior to the onset of headache. Whether these cyclic changes are associated with somatosensory alteration remains incompletely understood.
Methods: The present study aimed to investigate the temporal progression of somatosensory alterations preceding the onset of a migraine attack.
Evidence-based review and frontiers of migraine therapy.
Neurogastroenterol Motil
August 2024
Department of Neurology and Ophthalmology, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
Article Synopsis
- Cyclic vomiting syndrome (CVS) is linked to migraines and may share common biological mechanisms, like hypothalamic activation and altered dopamine signaling.
- Recent advancements in migraine treatments could also benefit CVS, despite limited research on their effectiveness for this condition.
- The manuscript focuses on emerging migraine therapies, including CGRP-targeting drugs and neuromodulation devices, which might be helpful for treating CVS in the future.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.
Front Pharmacol
June 2024
Shanghai Xuhui Central Hospital / Xuhui Hospital, Fudan University, Shanghai, China.
Heart failure is the most costly cardiovascular disorder. New treatments are urgently needed. This study aims to evaluate the safety, pharmacokinetics, and pharmacodynamic profile of HEC95468, a soluble guanylate cyclase (sGC) stimulator, in healthy volunteers.
View Article and Find Full Text PDFPituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.
Ann Clin Transl Neurol
July 2024
Headache Group, The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Objective: Migraine is a complex and disabling neurological disorder. Recent years have witnessed the development and emergence of novel treatments for the condition, namely those targeting calcitonin gene-related peptide (CGRP). However, there remains a substantial need for further treatments for those unresponsive to current therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!